RxDoctor Payments Data

Hussein Shaqra, MD

Cardiovascular Disease · Clifton, NJNPI 1922031574

Payments from drug & device makers

$15,623in general payments, 2019–2025

Across 461 payments — averaging $33.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$3K
  • Boehringer Ingelheim$3K
  • Abbott$1K
  • Abiomed$1K
  • Medtronic$903
  • Cardiovascular Systems Inc.$702
  • plus $6K from 37 others

What the payments were for

  • Travel & lodging$1,1509%
  • Food & beverage$11,34088%
  • Education$4333%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,623 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$291,618
Medicare patients
377
Services billed
2,654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan257$285,403
EliquisApixaban237$230,621
JardianceEmpagliflozin191$187,337
XareltoRivaroxaban126$121,204
BrilintaTicagrelor117$96,657
FarxigaDapagliflozin Propanediol68$63,613
OzempicSemaglutide39$55,889
Metoprolol Succinate1,025$15,362
Repatha SureclickEvolocumab21$12,153
EdarbyclorAzilsartan Med/Chlorthalidone25$10,556
Colchicine93$10,411
EdarbiAzilsartan Medoxomil27$9,820
Atorvastatin Calcium440$6,984
Ranolazine ErRanolazine60$5,845
Repatha SyringeEvolocumab17$5,802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$542$285,403257 claims
PfizerEliquis$171$230,621237 claims
Boehringer IngelheimJardiance$2,590$187,337191 claims
AstraZenecaBrilinta, Farxiga$564$160,270185 claims
Johnson & JohnsonXarelto$275$121,204126 claims
Novo NordiskOzempic$90$55,88939 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$25$20,37552 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →